Kimerik antijen receptorü (CAR-T) hücresi ve tedavide kullanımı
Öz
Anahtar Kelimeler
Kimerik Antijen Reseptör , hücre aracılı terapi , T hücre , hematolojik kanserler
Kaynakça
- Aly RM. Current state of stem cell-based therapies: an overview. Stem Cell Investig. 2020;7:8.
- El-Kadiry AE, Rafei M, Shammaa R. Cell therapy: types, regulation, and clinical benefits. Front Med (Lausanne). 2021;8:756029.
- Brown-Sequard C. Notes on the effects produced on man by sub-cutaneous injections of a liquid obtained from the testicles of animals. Lancet. 1889;134:105-7
- Wang LL, Janes ME, Kumbhojkar N, Kapate N, Clegg JR, Prakash S et al. Cell therapies in the clinic. Bioeng Transl Med. 2021;6:e10214.
- De Bousser E, Callewaert N, Festjens N. T Cell engaging immunotherapies, highlighting Chimeric Antigen Receptor (CAR) T cell therapy. Cancers (Basel). 2021;13:6067.
- Lei W, Xie M, Jiang Q, Xu N, Li P, Liang A et al. Treatment-related adverse events of Chimeric Antigen Receptor T-Cell (CAR T) in clinical trials: a systematic review and meta-analysis. Cancers (Basel). 2021;13:3912.
- Fischer JW, Bhattarai N. CAR-T cell therapy: mechanism, management, and mitigation of inflammatory toxicities. Front Immunol. 2021;12:693016..
- Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69.
- Lefrère JJ, Berche P. La thérapeutique du docteur Brown-Séquard. Ann Endocrinol (Paris). 2010;71:69–75.
- Bongso A, Richards M. History and perspective of stem cell research. Best Pract Res Clin Obstet Gynaecol. 2004;18:827-42.